2-naphthol has been researched along with bortezomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baggio, R; El Oualid, F; Fasci, D; Hedstrom, L; Lawson, AP; Long, MJC; Qian, Y; Rozhansky, L; Weerapana, E | 1 |
| Duhamel, LA; Eskandarpour, M; Flanagan, AM; Presneau, N; Tirabosco, R; Ye, H | 1 |
2 other study(ies) available for 2-naphthol and bortezomib
| Article | Year |
|---|---|
Diarylcarbonates are a new class of deubiquitinating enzyme inhibitor.
Topics: Carbonates; Deubiquitinating Enzymes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Molecular Structure; Structure-Activity Relationship; Ubiquitination | 2019 |
Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas.
Topics: AMP-Activated Protein Kinase Kinases; Anoikis; Antineoplastic Agents; Benzamides; Bone Neoplasms; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; MicroRNAs; Naphthols; Osteosarcoma; Protein Biosynthesis; Protein Serine-Threonine Kinases; RNA, Messenger; Signal Transduction; Sirtuin 1; TOR Serine-Threonine Kinases; Transfection | 2017 |